Johnson & Johnson
JNJ207.640USD
-0.140-0.07%
Fechamento 12/26, 16:00（ET）Cotações atrasadas em 15 min
499.62BValor de mercado
19.90P/L TTM
Mais detalhes de Johnson & Johnson Empresa
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Informações de Johnson & Johnson
Código da empresaJNJ
Nome da EmpresaJohnson & Johnson
Data de listagemOct 31, 2080
CEODuato (Joaquin Boix)
Número de funcionários138100
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 31
EndereçoOne Johnson & Johnson Plaza
CidadeNEW BRUNSWICK
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal08933
Telefone17325242455
Sitehttps://www.jnj.com/
Código da empresaJNJ
Data de listagemOct 31, 2080
CEODuato (Joaquin Boix)
Executivos da empresa Johnson & Johnson
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
12.85K
+17.90%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
--
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
--
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
--
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
--
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Oncology-DARZALEX
3.54B
14.91%
Immunology-STELARA
1.65B
6.96%
Cardiovascular-ELECTROPHYSIOLOGY
1.47B
6.18%
Surgery-General
1.39B
5.86%
Immunology-TREMFYA
1.19B
5.00%
Outro
14.51B
61.10%
Por RegiãoUSD
Nome
Receita
Proporção
United States
13.54B
57.04%
Europe
5.39B
22.69%
Asia-Pacific, Africa
3.61B
15.19%
Western Hemisphere, excluding U.S.
1.21B
5.08%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Oncology-DARZALEX
3.54B
14.91%
Immunology-STELARA
1.65B
6.96%
Cardiovascular-ELECTROPHYSIOLOGY
1.47B
6.18%
Surgery-General
1.39B
5.86%
Immunology-TREMFYA
1.19B
5.00%
Outro
14.51B
61.10%
Distribuição de ações
Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.78%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
Outro
75.51%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.78%
State Street Investment Management (US)
5.49%
BlackRock Institutional Trust Company, N.A.
5.37%
Geode Capital Management, L.L.C.
2.33%
JP Morgan Asset Management
1.52%
Outro
75.51%
Tipos de investidores
Investidores
Proporção
Investment Advisor
39.47%
Investment Advisor/Hedge Fund
24.27%
Research Firm
3.15%
Pension Fund
2.24%
Bank and Trust
2.16%
Insurance Company
1.61%
Sovereign Wealth Fund
1.41%
Hedge Fund
0.72%
Family Office
0.09%
Outro
24.88%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
5885
1.79B
74.44%
+16.50K
2025Q2
5920
1.78B
73.89%
-7.65M
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
236.03M
9.8%
+3.04M
+1.31%
Jun 30, 2025
State Street Investment Management (US)
132.80M
5.51%
-992.45K
-0.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
129.76M
5.39%
+619.12K
+0.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
60.61M
2.52%
+1.23M
+2.06%
Jun 30, 2025
JP Morgan Asset Management
36.71M
1.52%
+1.46M
+4.13%
Jun 30, 2025
State Farm Insurance Companies
34.37M
1.43%
--
--
Jun 30, 2025
Norges Bank Investment Management (NBIM)
31.93M
1.33%
+1.57M
+5.18%
Jun 30, 2025
Wellington Management Company, LLP
24.88M
1.03%
+2.23M
+9.85%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
25.30M
1.05%
+1.23M
+5.13%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
19.85M
0.82%
+148.42K
+0.75%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares U.S. Pharmaceuticals ETF
23.7%
VanEck Pharmaceutical ETF
10.06%
FT Vest DJIA Dogs 10 Target Income ETF
9.82%
Health Care Select Sector SPDR Fund
9.32%
Proshares Ultra Health Care
9%
iShares U.S. Healthcare ETF
8.9%
JPMorgan Healthcare Leaders ETF
8.38%
First Trust NASDAQ Pharmaceuticals ETF
8.28%
Fidelity MSCI Health Care Index ETF
7.67%
Franklin Income Focus ETF
7.08%
Ver Mais
iShares U.S. Pharmaceuticals ETF
Proporção23.7%
VanEck Pharmaceutical ETF
Proporção10.06%
FT Vest DJIA Dogs 10 Target Income ETF
Proporção9.82%
Health Care Select Sector SPDR Fund
Proporção9.32%
Proshares Ultra Health Care
Proporção9%
iShares U.S. Healthcare ETF
Proporção8.9%
JPMorgan Healthcare Leaders ETF
Proporção8.38%
First Trust NASDAQ Pharmaceuticals ETF
Proporção8.28%
Fidelity MSCI Health Care Index ETF
Proporção7.67%
Franklin Income Focus ETF
Proporção7.08%
Dividendo
Um total de
56.79B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de Johnson & Johnson?
Os cinco principais acionistas de Johnson & Johnson são:
The Vanguard Group, Inc. detém 236.03M Ações, representando 9.80% do total de Ações.
State Street Investment Management (US) detém 132.80M Ações, representando 5.51% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 129.76M Ações, representando 5.39% do total de Ações.
Geode Capital Management, L.L.C. detém 60.61M Ações, representando 2.52% do total de Ações.
JP Morgan Asset Management detém 36.71M Ações, representando 1.52% do total de Ações.
The Vanguard Group, Inc. detém 236.03M Ações, representando 9.80% do total de Ações.
State Street Investment Management (US) detém 132.80M Ações, representando 5.51% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 129.76M Ações, representando 5.39% do total de Ações.
Geode Capital Management, L.L.C. detém 60.61M Ações, representando 2.52% do total de Ações.
JP Morgan Asset Management detém 36.71M Ações, representando 1.52% do total de Ações.
Quais são os três principais tipos de acionistas de Johnson & Johnson?
Os três principais tipos de acionistas da Johnson & Johnson são:
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
Quantas instituições possuem ações da Johnson & Johnson (JNJ)?
Em 2025Q3, 5885 instituições possuíam ações da Johnson & Johnson, com valor de mercado aproximado de 1.79B, representando 74.44% do total de ações. Em comparação com 2025Q2, a participação institucional aumentou em 0.55%.
Qual é a maior fonte de receita da Johnson & Johnson?
Em FY2025Q2, o segmento de negócios Oncology-DARZALEX gerou a maior receita para Johnson & Johnson, totalizando 3.54B e representando 14.91% da receita total.
